What is BioCryst Pharmaceuticals's investment proceeds?

BioCryst Pharmaceuticals (BCRX) reported investment proceeds of $221.24M in Q1 2026.

How has BioCryst Pharmaceuticals's investment proceeds changed year-over-year?

BioCryst Pharmaceuticals's investment proceeds increased by 191.1% year-over-year, from $76M to $221.24M.

What is the long-term trend for BioCryst Pharmaceuticals's investment proceeds?

Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's investment proceeds has grown at a 73.7% compound annual growth rate (CAGR), from $28.2M to $256.65M.

What does investment proceeds mean?

Cash received from sales, maturities, and redemptions of investment securities across all categories.

BioCryst Pharmaceuticals BCRX Investment Proceeds

Investment Proceeds at other companies

Ionis PharmaceuticalsIONS

$752.82M+52.2%

Ultragenyx PharmaceuticalRARE

$88M-35.8%

AnaptysBio, Inc.ANAB

$35M-74.5%

BridgeBio PharmaBBIO

$10M—

Arrowhead ResearchARWR

$115.34M-2.4%

Agios PharmaceuticalsAGIO

$290.26M+0.7%

Other financials

Income statement

See full

Revenue$156.4M+7.5%

Gross profit$151.0M+7.1%

Operating income-$701.6M-3,405%

Net income-$721.8M-2,255,763%

EPS (diluted)-$2.98—

Balance sheet

See full

Cash & equivalents$173.4M+62.2%

Total debt$411.8M+24.7%

Total equity-$553.8M-22.6%

Total assets$465.1M-3.1%

Cash flow

See full

Operating cash flow-$61.8M-125%

CapEx$403.0K+182%

Free cash flow-$62.2M-125%

Valuation

See full

Market cap$2.37B+52.3%

Enterprise value$2.6B+46.7%

P/S2.7×-0.4×

Profitability

See full

Gross margin97.8%+0.8pp

Operating margin-43.1%-49.7pp

Net margin-51.7%-69.7pp

FCF margin35%—

Returns & leverage

See full

Return on equity-882.8%—

Debt / equity0.1×—

Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's investment proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioCryst Pharmaceuticals's investment proceeds?: BioCryst Pharmaceuticals (BCRX) reported investment proceeds of $221.24M in Q1 2026.
How has BioCryst Pharmaceuticals's investment proceeds changed year-over-year?: BioCryst Pharmaceuticals's investment proceeds increased by 191.1% year-over-year, from $76M to $221.24M.
What is the long-term trend for BioCryst Pharmaceuticals's investment proceeds?: Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's investment proceeds has grown at a 73.7% compound annual growth rate (CAGR), from $28.2M to $256.65M.
What does investment proceeds mean?: Cash received from sales, maturities, and redemptions of investment securities across all categories.